JP2024113183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024113183A5 JP2024113183A5 JP2024094996A JP2024094996A JP2024113183A5 JP 2024113183 A5 JP2024113183 A5 JP 2024113183A5 JP 2024094996 A JP2024094996 A JP 2024094996A JP 2024094996 A JP2024094996 A JP 2024094996A JP 2024113183 A5 JP2024113183 A5 JP 2024113183A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hae
- antibody
- prior
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725216P | 2018-08-30 | 2018-08-30 | |
| US62/725,216 | 2018-08-30 | ||
| US201962808612P | 2019-02-21 | 2019-02-21 | |
| US62/808,612 | 2019-02-21 | ||
| JP2021510984A JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| PCT/US2019/048961 WO2020047352A1 (en) | 2018-08-30 | 2019-08-30 | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510984A Division JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024113183A JP2024113183A (ja) | 2024-08-21 |
| JP2024113183A5 true JP2024113183A5 (enExample) | 2025-03-04 |
| JP7894905B2 JP7894905B2 (ja) | 2026-07-24 |
Family
ID=67953889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510984A Active JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
| JP2024094996A Active JP7894905B2 (ja) | 2018-08-30 | 2024-06-12 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510984A Active JP7585193B2 (ja) | 2018-08-30 | 2019-08-30 | 血漿カリクレイン阻害剤及び遺伝性血管浮腫発作を処置するためのその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109214A1 (enExample) |
| EP (1) | EP3843840A1 (enExample) |
| JP (2) | JP7585193B2 (enExample) |
| KR (1) | KR20210053928A (enExample) |
| CN (1) | CN113056304A (enExample) |
| AU (2) | AU2019328324B2 (enExample) |
| BR (1) | BR112021003789A2 (enExample) |
| CA (1) | CA3110689A1 (enExample) |
| IL (1) | IL281063A (enExample) |
| MA (1) | MA53490A (enExample) |
| MX (1) | MX2021002349A (enExample) |
| WO (1) | WO2020047352A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| EP3843840A1 (en) * | 2018-08-30 | 2021-07-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| KR102011156B1 (ko) * | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| JP2016513682A (ja) * | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| IL247942B (en) * | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| CA3290174A1 (en) * | 2015-03-30 | 2026-03-02 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| JP6885952B2 (ja) * | 2015-12-18 | 2021-06-16 | グラコ ミネソタ インコーポレーテッド | ベローズの取付けと保持方法 |
| EP3843840A1 (en) * | 2018-08-30 | 2021-07-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
-
2019
- 2019-08-30 EP EP19768977.1A patent/EP3843840A1/en active Pending
- 2019-08-30 MX MX2021002349A patent/MX2021002349A/es unknown
- 2019-08-30 JP JP2021510984A patent/JP7585193B2/ja active Active
- 2019-08-30 KR KR1020217009365A patent/KR20210053928A/ko not_active Ceased
- 2019-08-30 US US16/556,524 patent/US20200109214A1/en not_active Abandoned
- 2019-08-30 AU AU2019328324A patent/AU2019328324B2/en active Active
- 2019-08-30 WO PCT/US2019/048961 patent/WO2020047352A1/en not_active Ceased
- 2019-08-30 MA MA053490A patent/MA53490A/fr unknown
- 2019-08-30 CA CA3110689A patent/CA3110689A1/en active Pending
- 2019-08-30 CN CN201980072190.9A patent/CN113056304A/zh active Pending
- 2019-08-30 BR BR112021003789-6A patent/BR112021003789A2/pt unknown
-
2021
- 2021-02-23 IL IL281063A patent/IL281063A/en unknown
-
2022
- 2022-05-16 US US17/745,770 patent/US20230104754A1/en active Pending
-
2024
- 2024-06-12 JP JP2024094996A patent/JP7894905B2/ja active Active
-
2025
- 2025-09-15 AU AU2025230807A patent/AU2025230807A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535161A5 (enExample) | ||
| JP2022033868A5 (enExample) | ||
| Gurfinkel et al. | Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study | |
| JP2019501886A5 (enExample) | ||
| US20240052058A1 (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| JP2022525164A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| Weitz | Factor XI and factor XII as targets for new anticoagulants | |
| Reisch et al. | Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function | |
| JP2018514510A5 (enExample) | ||
| Papp et al. | Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial | |
| JP2023510854A5 (enExample) | ||
| UA127588C2 (uk) | Способи застосування та композиції, які містять дулаглутид | |
| JP2026500140A (ja) | 血漿カリクレイン関連障害を処置するための抗血漿カリクレイン抗体投薬レジメン | |
| JP2021522241A5 (enExample) | ||
| US5977160A (en) | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims | |
| JP7709970B2 (ja) | 遺伝性血管性浮腫の治療または予防のための抗第ｘｉｉ因子抗体の使用 | |
| JP2024522620A5 (enExample) | ||
| JP2023519501A5 (enExample) | ||
| NZ783274B2 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| NZ783274A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| Cohn et al. | Clinical evidence with garadacimab demonstrates no impact on hemostasis | |
| RU2021129732A (ru) | Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека | |
| RU2026104179A (ru) | Способы лечения множественной миеломы | |
| US20210338766A1 (en) | Methods of treating multiple myeloma |